Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $58.58, for a total value of $352,534.44. Following the completion of the transaction, the chief financial officer owned 40,036 shares of the company’s stock, valued at $2,345,308.88. The trade was a 13.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Friday, July 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $52.64, for a total transaction of $316,787.52.
• On Wednesday, June 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $43.80, for a total transaction of $263,588.40.

Enliven Therapeutics Stock Performance

ELVN stock opened at $58.92 on Friday. The company’s fifty day moving average price is $52.72 and its 200-day moving average price is $41.84. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $62.32. The company has a market capitalization of $4.32 billion, a PE ratio of -35.28 and a beta of 0.27.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, research analysts predict that Enliven Therapeutics, Inc. will post -1.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. Guggenheim dropped their price objective on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. William Blair started coverage on shares of Enliven Therapeutics in a report on Tuesday. They issued an “outperform” rating on the stock. HC Wainwright upped their price objective on Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Finally, Mizuho lifted their target price on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a report on Tuesday. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

Institutional Trading of Enliven Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ELVN. Mirae Asset Global Investments Co. Ltd. boosted its stake in Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after acquiring an additional 594 shares in the last quarter. Invesco Ltd. grew its position in Enliven Therapeutics by 4.3% during the 2nd quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock worth $440,000 after purchasing an additional 913 shares during the last quarter. BNP Paribas Financial Markets grew its position in Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the last quarter. KBC Group NV acquired a new position in Enliven Therapeutics during the 1st quarter valued at approximately $38,000. Finally, Swiss National Bank increased its stake in Enliven Therapeutics by 1.7% during the 4th quarter. Swiss National Bank now owns 64,273 shares of the company’s stock valued at $990,000 after purchasing an additional 1,100 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.